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The major immediate-early (MIE) genes of cytomegaloviruses (CMV) are broadly thought to be decisive
regulators of lytic replication and reactivation from latency. To directly assess the role of the MIE protein IE1
during the infection of murine CMV (MCMV), we constructed an MCMV with exon 4 of the ie1 gene deleted.
We found that, independent of the multiplicity of infection, the resulting recombinant virus, MCMVdie1, which
fails to express the IE1 protein, was fully competent for early gene expression and replicated in different
cultured cell types with identical kinetics to those of parental or revertant virus. Immunofluorescence micros-
copy studies revealed that MCMVdie1 was greatly impaired in its capacity to disrupt promyelocytic leukemia
bodies in NIH 3T3 cells early after infection, a process that has been proposed to increase viral transcription
efficiency. We examined MCMVdie1 in the murine model using both immunocompetent BALB/c and severe
combined immunodeficient (SCID) mice. When MCMVdie1 was inoculated into these two types of mice,
significantly lower viral titers were detected in infected organs than in those of the wild-type virus-infected
animals. Moreover, the ie1-deficient MCMV exhibited a markedly reduced virulence. While all animals infected
with 5  104 PFU of parental virus died by 30 days postinfection, SCID mice infected with a similar dose of
MCMVdie1 did not succumb before 60 days postinfection. The in vivo defective growth phenotype of MCMV-
die1 was abrogated upon rescue of ie1. These results demonstrate the significance of the ie1 gene for promoting
an acute MCMV infection and virulence yet indicate that MCMV is able to grow in vivo, although impaired,
in the absence of the ie1 gene.
Similar to other herpesviruses, the transcription of the cyto-
megalovirus (CMV) genome during the lytic infection is tem-
porarily regulated (for a review, see reference 47). The imme-
diate-early (IE or ) genes are the first ones to be expressed in
the replicative cycle, and their expression does not depend on
prior viral protein synthesis. Together with some virion pro-
teins, the IE products activate viral genes and alter the infected
cell to generate an appropriate milieu that favors viral repli-
cation. Transcription of early (E or ) genes requires the
expression of at least one of the IE proteins, and only after
viral replication has started, the transcription of late (L or )
genes proceeds. The majority of the CMV IE transcripts orig-
inate from the major IE (MIE) locus. This locus is structurally
similar between human CMV (HCMV) and the closely related
mouse CMV (MCMV) (14, 53, 59). The primary transcript
from the MIE region is under the control of the strong MIE
enhancer-promoter and is differentially spliced to generate two
predominant transcripts, the ie1 transcript that consists of ex-
ons 1 to 4, and the ie2 transcript that is composed of exons 1 to
3 and 5. In HCMV, the ie1 and ie2 transcripts are translated
into the acidic 72-kDa IE1 and the 86-kDa IE2 nuclear phos-
phoproteins, respectively (for a review, see reference 59). The
corresponding IE transcripts of MCMV encode the acidic 89-
kDa IE1 phosphoprotein and the 88-kDa IE3 protein (33, 34,
45).
The MIE proteins of HCMV display multiple functions (for
reviews, see references 19 and 47). Mostly based on data from
transient transfection assays and in vitro analysis, these viral
products have been shown to be promiscuous regulatory pro-
teins. In particular, HCMV IE2 is capable of down-regulating
transcription from its own promoter by binding to the cis re-
pression signals and exhibits strong transactivating properties
on HCMV early promoters as well as on heterologous viral
promoters. This gene product has been also shown to transac-
tivate a number of host genes, such as the thymidine kinase
gene or the dihydrofolate reductase gene. A number of com-
ponents of the basal transcription machinery (i.e., TBP, TFIIB,
TFIID) and cellular transcription factors (i.e., CREB, CBP,
c-Jun) have been reported to directly interact with HCMV IE2
(11, 25, 31, 39, 57). HCMV IE1, the most abundant IE product,
autostimulates the MIE enhancer-promoter (15, 59, 60, 62),
plays an accessory role in the IE2-mediated activation of
HCMV early and late genes (40, 62), and increases transcrip-
tion of the long terminal repeat of human immunodeficiency
virus (67). It can also transactivate a limited number of cellular
promoters, including the ones corresponding to the DNA poly-
merase  (26), dihydrofolate reductase (65), and prointerleu-
kin-1 (29). Interaction of HCMV IE1 with a number of cel-
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lular regulatory proteins (i.e., CTF-1, p107) has also been
described previously (51). In addition to their regulatory activ-
ities, HCMV IE1 and IE2 are involved in perturbing a variety
of other cellular processes, including cell cycle regulation (10,
69), apoptosis (71), and cell architecture. In this connection,
IE1 has been shown to interact with chromatin and to cause
the dispersion of the promyelocytic leukemia (PML) protein-
associated nuclear bodies known as PML oncogenic domains,
nuclear domain 10, or PML bodies (1, 2, 30, 35, 70). Though
the precise role of these structures has not been defined, it has
been hypothesized that they are part of a host cell repression
system for viral infections.
In recent years, advances in the methodology that permits
the manipulation of the CMV genome, in particular the appli-
cation of the bacterial artificial chromosome (BAC) technol-
ogy has enormously facilitated the generation of CMV mutants
(6, 46). This has made it possible to begin elucidating the
biological significance of the MIE locus during the course of
CMV infection. In agreement with the multifunctional nature
assigned to the MIE proteins, it has been found that HCMVs
with deletions in either the ie1 or the ie2 gene exhibit severe
phenotypes in cultured cells. Marchini and coworkers (41)
reported that a recombinant virus lacking the majority of the
ie2 gene was blocked at the early phase of gene expression and
did not produce infection progeny. A number of other HCMV
with defects in the ie2 gene have been generated and essen-
tially have corroborated the importance of IE2 in the control
of viral gene expression (27, 56, 68). Deletion of the ie1 gene of
HCMV causes a drastic growth defect under conditions of low
multiplicity of infection of primary fibroblasts (24, 48). This
growth deficiency appears to be the result of a broad reduction
of delayed-early gene transcription in the absence of functional
IE1 and can be circumvented at a high viral input (20).
Due to the species specificity of HCMV, MCMV replication
in mice has been extensively employed as a well-established
model system for the study of different aspects of HCMV
pathogenesis, latency, and reactivation. However, a limited
number of studies have addressed MCMV IE activities. Similar
to its HCMV IE2 homologue, MCMV IE3 represents the
master switch that determines the transition from IE to E
expression, and accordingly, MCMV ie3-deficient mutants are
completely replication defective (3). The fact that the IE1
proteins of human and murine CMV exhibit a very similar
global molecular structure, despite sharing little homology be-
tween their nucleic acid or amino acid sequences, has led to the
assumption that they might have analogous functions during
the course of the infection (33, 34, 60, 61). In this respect,
MCMV IE1 has been reported to activate heterologous pro-
moters (36) and to cooperate with IE3 protein in the activation
of MCMV early gene promoters (45). In a recent study, Tang
and Maul (63) have reported that MCMV IE1, as in the
HCMV system, localizes to PML bodies and disperses them.
Moreover, these studies reported on the ability of MCMV IE1
to bind to host cell repressors and proposed that the levels of
IE1 expression might determine the number of repressed/ac-
tivated viral genomes and, hence, the efficiency of a productive
MCMV infection. An MCMV with a frameshift in exon 4 of
the ie1 gene that leads to a truncated IE1 protein has been
constructed (46) and was shown to have some growth impair-
ment on cultured fibroblasts. However, the phenotype of this
recombinant virus has not been further analyzed, and the pres-
ence of BAC sequences replacing genomic regions required for
the in vivo infection has restricted its use in mice. Thus, the
precise roles exerted by this protein during the MCMV life
cycle still remain elusive. Moreover, the contribution that IE1
makes to in vivo MCMV growth and pathogenesis is unknown.
In the present study, we have directly addressed the rele-
vance of IE1 on the replicative strategies of MCMV in vitro
and in the natural host. Using a parental full-length MCMV
genome, we have created and characterized an MCMV devoid
of exon 4 of the ie1 gene and, hence, unable to synthesize the
IE1 protein. We found that this recombinant virus replicated
as efficiently as the parental or revertant MCMV in different
cell types in culture. In contrast, the ie1-deficient MCMV
showed a significantly attenuated in vivo replication capacity
and virulence. Thus, the MCMV IE1 protein is not essential
but promotes efficient viral growth in mice.
MATERIALS AND METHODS
Cells and viruses. The murine fibroblast cell line NIH 3T3 (ATCC CRL-
1658), the mouse epithelial tumor cell line C127I (ATCC CRL-1616), and the
mouse endothelial cell line SVEC4 (ATCC CRL-2161) were obtained from the
American Type Culture Collection (Manassas, VA.). Primary mouse embryonic
fibroblasts (MEFS) were prepared from the embryos of pregnant BALB/c.ByJ
mice on day 19 of gestation. Primary macrophages were elicited from peritoneal
exudate cells following intraperitoneal injection of 1 ml thioglycolate (Becton
Dickinson, Cockeysville, MD) into BALB/c.ByJ mice. Peritoneal exudate cells
were removed by peritoneal lavage, plated out at 1  106 to 5  106/ml, and
incubated for 24 to 48 h at 37°C, 5% CO2, after which nonadherent cells were
washed away with phosphate-buffered saline (PBS). Cells were cultured in Dul-
becco’s modified essential medium (DMEM) supplemented with 2 mM glu-
tamine, 100 U of penicillin per ml, 100 g of gentamicin per ml, and 10% fetal
bovine serum, except for the NIH 3T3 cells, where calf serum was used instead.
The parental BAC-derived MCMV strain MW97.01 (named MCMV in this
study) (66) and the recombinant MCMVs generated in the course of the study
were propagated on NIH 3T3 cells. The ie3-deficient mutant MCMVdie3 was
described by Angulo et al. (3).
Plasmid construction. A 5.4-kbp EcoRI fragment from plasmid pIE3 (45)
was cloned into the shuttle vector pST76ASacB (3) to get the recombination
plasmid pST76ASie1. The 5.4-kbp EcoRI fragment comprises the ie3 gene with
exons 3 and 5 of the M122/123 genes directly fused to each other (nucleotides
[nt] 177008 to 179517 and 181372 to 184236 of the MCMV genome) (53).
Plasmid pST76KSRie1r, which was used for construction of a revertant virus, was
generated by insertion of a 7.2-kbp EcoRI fragment (nt 177008 to 184236) (53)
obtained from plasmid pIE111 (45) into shuttle plasmid pST76-KSR, a derivative
of pST76K (52) carrying the negative selection marker sacB and the recA gene.
To generate another rescuant virus that could be distinguished from the wild-type
MCMV, the 1.5-kbp AvrII fragment (nt 180489 to 182002) in plasmid pIE111 was
replaced by an SpeI-AvrII-treated DNA fragment which was obtained by PCR
using primers Avr.for (5-CTG AAT TCC TAG GCC CTG ACA GAA AAA
AGG-3) and AvrSpe.rev (5-CTG AAT TCA CTA GTC ATG GTG AAG CTA
TCA AAG A-3). Correct insertion of the PCR fragment destroyed the AvrII
site at position 180489. The integrity of the insert was checked by sequencing.
Finally, the 7.2-kbp EcoRI fragment of the modified pIE111 plasmid was trans-
ferred to pST76-KSR as described above, leading to pST76KSRie1r-2.
BAC mutagenesis and reconstitution of recombinant viruses. Recombination
between the full-length MCMV BAC pSM3fr (66) and the recombination plas-
mid pST76ASie1 was performed by a two-step replacement procedure in the
Escherichia coli strain CBTS essentially as described previously (3) to gener-
ate the mutant MCMV BAC pSM3frdie1. To restore the ie1 gene, the BAC
pSM3frdie1 was transferred into the E. coli strain DH10B and recombination
was performed using plasmid pST76KSRie1r. A second revertant virus that could
be distinguished from the wild-type MCMV by AvrII digestion of the viral
genomes was generated by using plasmid pST76KSRie1r-2. Since both rescuants
led to equivalent results, only data obtained with one virus (MCMVrev) are
discussed in Results. BACs carrying the desired mutation were identified by
restriction enzyme analysis and agarose gel electrophoresis as described previ-
ously (4). Midi preparations of BAC DNA were obtained from 100-ml E. coli










cultures using Nucleobond PC100 columns (Macherey-Nagel, Du¨ren, Germany)
according to the instructions of the manufacturer. Recombinant viruses were
reconstituted by transfection of the BAC DNA into NIH 3T3 cells using the
calcium phosphate transfection method.
In vitro growth of recombinant MCMVs. Cells in 24-well plates were infected
with the different recombinant viruses at the indicated multiplicities of infection
(MOIs). After a 1-h adsorption period, cells were washed with PBS and incu-
bated in DMEM supplemented with either 3% fetal bovine serum or 3% calf
serum (in the case of the NIH 3T3 cells). The supernatants of the infected cells
were collected at the different times postinfection, cleared of cellular debris, and
frozen at 70°C. Virus titers were subsequently determined by plaque assay on
NIH 3T3 cells. In the case of peritoneal macrophages, intracellular viral titers
were measured.
Western blotting analyses. NIH 3T3 cells (in six-well dishes) were either mock
infected or infected with the different MCMV recombinants at an MOI of 5
PFU/cell. At 6 and 24 h postinfection, samples were lysed in protein sample
buffer, vortexed, and boiled for 5 min. For selective expression of IE proteins, the
cells were exposed for 30 min before the infection, during viral adsorption, and
for 3 h after infection to cycloheximide (CHX, 50 g/ml), at which time point the
CHX was replaced with actinomycin D (5 g/ml). Actinomycin D was main-
tained in these cultures until the cells were harvested (7 h postinfection). The
polypeptides of cell lysates were separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (7.5% polyacrylamide) and transferred to nitrocellu-
lose filters. Equal quantities of total protein were analyzed per lane. Filters were
incubated with mouse anti-IE1 or anti-E1 specific monoclonal antibodies, Croma
101 and Croma 103, respectively, or a rabbit IE3-specific antiserum. As second-
ary antibodies, horseradish peroxidase-conjugated goat anti-mouse immunoglob-
ulin G (Amersham, Buckinghamshire, England) and horseradish peroxidase-
conjugated goat anti-rabbit immunoglobulin G (Bio-Rad Laboratories, CA)
were used. Blots were developed by using the Enhancer chemiluminescence
system (Amersham) according to the manufacturer’s protocol.
Immunochemistry. NIH 3T3 cells were cultured on coverslips and infected
with the various MCMV recombinants at an MOI of 0.3 or 1. After 4, 15, or 24 h,
cells were rinsed once in PBS and fixed in 2% paraformaldehyde. Cells were
stained with primary antibody Croma 101 or Croma 103 and with rabbit anti-
PML (kind gift of P. Freemont). For secondary antibodies, fluorescein isothio-
cyanate-conjugated anti-rabbit and tetramethyl rhodamine isothiocyanate-con-
jugated anti-mouse (Jackson Laboratories) antibodies were applied. DNA was
counterstained with 4,6-diamidino-2-phenylindole (DAPI).
Epifluorescence microscopy and quantification. Images were taken with an
epifluorescence microscope using applied images software. For quantification
purposes, a series of images spanning the nuclei were taken using the 40 lens
and a z-step size of 0.8 m. Z sections were projected to a single image, and the
numbers of PML bodies in noninfected and infected cells were counted. To
discriminate intranuclear PML from cytoplasmic signal at 24 h after infection,
three-dimensional images were taken with a 100 lens and a z-step size of 0.3
m. Only those PML bodies residing within the DAPI-stained nuclei were
counted.
Viral nucleic acid isolation and analysis. Preparation of total DNA from
infected cells, restriction enzyme analysis, and gel electrophoresis were essen-
tially done as described previously (3). To examine whether a correct excision of
the BAC vector sequences from the recombinant MCMV genomes had occurred,
PCRs were performed as described previously (22, 66). Primers b (5-GCC CGC
CTG ATG AAT GCT C-3) and g (5-GGA TAC TCA GCG GCA GTT
TGC-3), which bind in the BAC vector sequences and in the EcoRI g fragment,
respectively, were used to amplify a 1,950-bp PCR fragment within the BAC-
containing genomes. Primers f (5-GGT TAC TGG ATG GGT ACG AG-3)
and g, which anneal with viral sequences flanking the excision site, were used to
detect a 590-bp product after successful excision of the BAC vector segment
from the viral genomes. The template used in the PCR was genomic DNA
isolated either from cells infected with the recombinant viruses or from a full-
length MCMV BAC plasmid. PCRs were performed under the following condi-
tions: 1 cycle at 94°C for 3 min; 30 cycles of 1 min at 94°C, 1 min at 58°C, and 1
min at 72°C; and 1 cycle at 72°C for 10 min. For Southern blot analysis, the
full-length MCMV BAC and DNA isolated from cells infected with the recom-
binant viruses were digested with MluI, separated on a 0.7% agarose gel, blotted
onto a HybondXL nylon membrane (Amersham Pharmacia), and hybridized
with a 32P-labeled probe corresponding to nt 216031 (MluI) to 218468 (NotI) of
the MCMV BAC genome.
Mouse infections. Six-week-old female BALB/c.ByJ or BALB/cAnNCrl mice
were obtained from the Scripps Research Institute breeding colony and Charles
River Labs (Lyon, France), respectively. Four-week-old female CB17 SCID mice
were obtained from Taconic Farms (N.Y.). Animals were housed in the vivarium
(The Scripps Research Institute or The University of Barcelona) under specific-
pathogen-free conditions. Mice were inoculated with 1  106 PFU of tissue
culture-derived MCMV recombinants by the intraperitoneal route. At desig-
nated times after infection, mice were sacrificed and organs were removed,
weighed, and harvested as a 10% (wt/vol) tissue homogenate. Tissue homoge-
nates were sonicated and centrifuged, and viral titers from the supernatants were
determined on NIH 3T3 cells by standard plaque assays. To assess levels of
virulence, the lethalities in CB17 SCID mice of mutant, parental, or revertant
MCMV (tissue culture derived) were compared. Animals were intraperitoneally
inoculated with 5  104 PFU of the different viruses, and their survival was
monitored daily.
RESULTS
Construction of MCMVdie1, an MCMV recombinant with
exon 4 of the ie1 gene deleted. To start examining the role of
IE1 during MCMV replication, we decided to construct an
MCMV with a deletion of the entire exon 4 of the ie1 gene. An
MCMV with a frameshift mutation in exon 4 of the ie1 gene
was previously reported (46). However, in addition to the ie1
alteration, this viral mutant generated using the BAC mu-
tagenesis technique contains BAC vector sequences replacing
a set of viral open reading frames (m151 to m158) that have
been shown to be required for optimal in vivo growth of
MCMV (66). Because a major objective of this study was to
analyze the importance of the ie1 gene during the acute CMV
infection, we undertook the construction of a new ie1-defective
MCMV based on the MCMV BAC pSM3fr that contains the
complete MCMV genome (66). Transfection of pSM3fr into
permissive cells results in viral progeny with in vivo growth
properties indistinguishable from those of wild-type MCMV.
To disrupt the IE1 open reading frame, we introduced a 1.8-
kbp deletion (from nt 179517 to nt 181372 of the MCMV
genome) (53) into the cloned MCMV genome using the re-
combination procedures in E. coli as described in Materials
and Methods. In this BAC recombinant genome, named
pSM3frdie1, exons 3 and 5 of the MCMV ie1/ie3 transcrip-
tion unit were fused, resulting in the complete removal of the
fourth exon (Fig. 1A, line 2). In addition, we made a revertant
genome by restoring the IE1 open reading frame. The rever-
tant genome, designated pSM3frdie1-rev, was constructed to
corroborate that the phenotype associated with the MCMVdie1
genome was due exclusively to the designed deletion in the ie1
gene and not because other alterations were present in the
mutant viral genome. In this recombinant BAC, sequences
from nt 179517 to nt 181372 of the MCMV genome were
reintroduced into the MCMVdie1 genome (Fig. 1A, line 3).
To confirm the genomic structure of the recombinant BACs
constructed, their HindIII restriction patterns were examined.
As shown in Fig. 1B, the natural 7.6-kbp HindIII K and the
7.2-kbp HindIII L fragments of the parental BAC pSM3fr were
replaced by a 12-kbp fragment in pSM3frdie1 (Fig. 1B, com-
pare lanes 1 and 2). Rescue of the ie1 gene in the revertant
BAC pSM3frdie1-rev led to the reappearance of the natural
HindIII K and L fragments (Fig. 1B, compare lanes 1 and 3).
Further characterization of the MCMV BACs generated was
carried out by digestion with additional restriction enzymes
(data not shown). These results indicated that the expected
recombination events took place within the ie1 region and that
no major deletions or rearrangements had occurred elsewhere
in the viral genome.
Next, we transfected the three MCMV BAC recombinants










into NIH 3T3 cells to reconstitute the corresponding viruses.
In all cases, numerous plaques appeared after transfection,
spreading quickly through the entire cultures. The progeny
viruses were harvested when the cultures reached cytopathic
effect, used to infect new cell monolayers, and plaque purified
three times. Viral stocks of each of the MCMV recombinants
were prepared, and the structure of their genomes was con-
firmed by restriction digestions. The patterns of restriction
obtained for the three genomes were as predicted and identical
to those of the corresponding BACs (data not shown). The
viruses generated were named MCMV (derived from pSM3fr),
MCMVdie1 (derived from pSM3frdie1), and MCMVrev (de-
rived from pSM3frdie1-rev).
Absence of IE1 protein expression in cells infected with
MCMVdie1. We next determined whether deletion of exon 4
of the ie1 gene in MCMVdie1 had resulted in the complete loss
of IE1 protein expression in infected cells. In MCMV-infected
cells, the 89-kDa IE1 protein is already detectable 1 h after
infection and is expressed during the whole replication pro-
gram (32, 45). NIH 3T3 cells were infected at a high MOI with
either MCMVdie1 or the parental or the revertant MCMV,
and cell lysates were prepared at 6 h and 24 h after infection.
Since IE proteins can be overexpressed by arresting the
MCMV-infected cells in the IE phase, we also infected NIH
3T3 cells in the presence of CHX to allow IE RNA transcrip-
tion but prevent synthesis of IE proteins. Three hours after
infection, the CHX was removed from these cultures, and
actinomycin D was added for 4 h to inhibit IE viral RNA
transcription, permitting protein synthesis of accumulated
RNAs. Samples were analyzed for IE1 expression by Western
blotting employing an MCMV IE1-specific monoclonal anti-
body. As shown in Fig. 2, the 89-kDa IE1 protein was detected
in lysates of cells infected with the parental or revertant
MCMV under IE conditions and at 6 h and 24 h postinfection.
However as expected, the IE1-specific antibody failed to rec-
ognize the IE1 polypeptide in lysates of infected cells with
MCMVdie1 under any of the conditions tested. Similar con-
clusions regarding the presence/absence of the IE1 protein in
the NIH 3T3 cells infected with the different recombinant
viruses could be drawn from immunofluorescence assays (see
Fig. 5A, panels c, e, and g).
Because construction of MCMVdie1 involved the fusion of
FIG. 1. Construction of an MCMV BAC genome lacking exon 4 of the ie1 gene. (A) Schematic representation of the parental pSM3fr, pSM3frdie1,
and the revertant pSM3frdie1-rev BAC. The HindIII map of the MCMV genome is shown at the top. The expanded map of the HindIII K and
HindIII L fragments represents the MCMV MIE gene region. Coding exons are shown as black rectangles, and the first noncoding exon of the ie1/ie3
transcription unit is shown as an white rectangle. The gray box represents the MCMV enhancer ie1/ie3 promoter. The structures of the ie1 and
ie3 transcripts are indicated below line 1 (of the expanded map). Starting with the parental BAC pSM3fr (line 1), the mutant BAC pSM3frdie1
(line 2) and the revertant BAC pSM3frdie1-rev (line 3) were generated by successive rounds of homologous recombination in E. coli as described
in Materials and Methods. The deletion of the fourth exon of the ie1 gene is marked by the delta (	). The sizes of the natural HindIII K and L fragments
in pSM3fr and pSM3frdie1-rev and that of the new HindIII fragment in pSM3frdie1 are indicated. (B) Genomic structure of pSM3fr, pSM3frdie1, and
pSM3frdie1-rev. Ethidium bromide-stained 0.7% agarose gel of HindIII-digested BACs pSM3fr (lane 1), pSM3frdie1 (lane 2), and pSM3frie1-rev
(lane 3). Size markers are indicated in the left margin. The names of the MCMV HindIII fragments (16) are shown in the right margin.










exons 3 and 5 of the MCMV ie1/ie3 transcription unit, we next
examined IE3 expression levels in MCMVdie1-infected NIH
3T3 cells by Western blotting using an IE3-specific antiserum.
As shown in Fig. 2, levels of the 88-kDa IE3 protein (45) were
comparable for MCMVdie1, parental, and revertant virus
throughout the three stages of the viral infection analyzed,
although we must note that in some experiments a slightly
higher amount (below 1.6-fold) of this viral product was de-
tected at the IE phase in cells infected with MCMVdie1 than
in cells infected with the corresponding control viruses. Finally,
we determined the expression of the MCMV early gene e1 in
these samples utilizing an E1-specific monoclonal antibody (8).
Accordingly, the 36- to 38-kDa E1 protein was expressed at
similar levels in cells infected for 6 h and 24 h by the ie1-
deficient MCMV than in parental and revertant MCMV-
infected cells (Fig. 2). Altogether, these results demonstrate
that deletion of exon 4 of the ie1 gene in MCMVdie1 resulted
in an IE1 protein-deficient virus and did not significantly alter
IE3 or early (E1) gene expression.
Growth phenotype of MCMVdie1 in cell culture. Having
confirmed the identity of the recombinant MCMVdie1, we
studied its growth properties in more detail. First, we com-
pared the growth kinetics of the mutant virus in NIH 3T3 cells
with that of the parental and revertant MCMVs. Because it has
been previously shown that, in the absence of ie1, the replica-
tion ability of both HCMV and MCMV on fibroblasts was
significantly impaired at low MOIs (24, 46, 48), we infected
NIH 3T3 cells with a reduced level of the recombinant viruses
(MOI, 0.01 PFU/cell). At various times postinfection, viral
titers from cultured supernatants were determined. Surpris-
ingly, the growth characteristics of MCMVdie1 were indistin-
guishable from those of the parental or revertant MCMV (Fig.
3, panel A). Equivalent results were obtained when the infec-
tions were performed under high-MOI conditions (Fig. 3,
panel B).
To assess whether the absence of phenotype of MCMVdie1
was specific of NIH 3T3 cells, we examined the growth kinetics
of this mutant virus on various cell lines known to play a role
in CMV biology in vivo. To this end, we infected mouse em-
bryo fibroblasts, peritoneal macrophages, a murine endothelial
cell line (SVEC4), and an epithelial cell line (C127I) with the
ie1-deficient MCMV at a low MOI. As shown in Fig. 4, mul-
tistep growth curves demonstrate that the replication kinetics
and infectivity yields of the ie1-deficient MCMV were very
similar to the ones exhibited by its parental or revertant virus
in the different cell types. Although viral titers attained in the
peritoneal macrophages were low and subjected to some fluc-
FIG. 2. Absence of IE1 protein in cells infected with MCMVdie1.
NIH 3T3 cells were either mock infected (M) or infected with the
parental MCMV (lanes 1), MCMVdie1 (lanes 2), or MCMVrev (lanes
3) at an MOI of 5 PFU/cell in the absence or presence of cyclohexi-
mide (CHX) as indicated in Materials and Methods. CHX-treated
samples were subsequently exposed to CHX for the 3 h after the
adsorption period, at which time the CHX was removed and actino-
mycin D was added for 4 h before the cells were harvested at 7 hpi. At
the time points after infection indicated (7 h for the CHX samples),
cells were lysed, subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis analysis on 7.5% polyacrylamide gels and Western
blots performed with anti-IE1 (IE1)- or anti-E1 (E1)-specific mono-
clonal antibodies or an IE3-specific antiserum (IE3).
FIG. 3. Growth of MCMVdie1 in NIH 3T3 cells. NIH 3T3 cells
were infected at an MOI of 0.01 (A) or 2 (B) PFU/cell with the pa-
rental MCMV, MCMVdie1, or MCMVrev. Culture supernatants were
collected at the indicated times after infection (days postinfection
[dpi]) and titrated by standard plaque assays on NIH 3T3 cells. Each
data point represents the average and standard deviation of results
from three separate cultures.
FIG. 4. Multistep growth curves of MCMVdie1 on different cell
types. Mouse embryonic fibroblasts, SVEC4 cells, C127I cells, and
peritoneal macrophages were infected with 0.05 PFU/cell, except for
macrophages, which were infected at an MOI of 0.5 PFU/cell, of
parental MCMV, MCMVdie1, or MCMVrev. Culture supernatants
were collected at the designated times postinfection (days postinfec-
tion [dpi]) and titrated by plaque assays on NIH 3T3 cells. In the case
of peritoneal macrophages, intracellular viral titers were determined.
Each data point represents the average and standard deviation of
results from three separate cultures.










tuations, the data presented here and obtained in an indepen-
dent experiment generally indicate that mutant, parental, and
revertant MCMVs replicate in a comparable manner in these
cells. Thus, the IE1 protein is completely dispensable for in
vitro MCMV growth.
Reduced capacity of MCMVdie1 to disperse PML bodies at
early times after infection. HCMV IE1 has been shown to
disrupt PML bodies (1, 2, 30, 35, 70). Recently, Tang and Maul
have reported that very early in MCMV infection or after
transfection with MCMV IE1, this protein concentrates at
PML bodies and then disperses these nuclear structures, sim-
ilar to its HCMV counterpart (63). We therefore examined the
ability of MCMVdie1 to disrupt PML bodies in permissive
NIH 3T3 cells. We infected NIH 3T3 monolayers at an MOI of
0.3 with either MCMVdie1 or the parental or revertant
MCMV, fixed cells at different times postinfection (4, 15, or
24 h), and stained them for PML and IE1 or the early MCMV
gene product E1 (8). We first confirmed that the parental and
revertant MCMV had disrupted PML bodies 4 h after infec-
tion (Fig. 5A, panels c and d [parental] and g and h [rever-
tant]). Noninfected cells in the same field showed PML bodies
similar to mock-infected cells (compare panels c, d, g, and h
with panels a and b). As expected, MCMVdie1-infected cells
did not express IE1 (panel e in Fig. 5A). Since in this case we
could not identify infected cells by the IE1 antibody, we used
the E1 antibody that allows the detection of the viral product
E1 as a punctate staining within the nucleus at this early time
point after infection (Fig. 5A, panels m and o). The number
of PML bodies in MCMVdie1- and mock-infected samples
showed no difference at 4 h postinfection (hpi) (Fig. 5B; for
image, Fig. 5A, panels k, o, and p). They contained the same
range of PML bodies per cell (MCMVdie1, 3 to 17; mock, 2 to
20), while MCMV and MCMVrev showed 0 to 3 PML bodies
per cell. This clearly shows that MCMVdie1 is not capable of
significantly disrupting PML bodies at 4 hpi. Similar results
were obtained when cells were infected with the three viruses
at an MOI of 1 (number of PML bodies per cell: mock, 2 to 23;
MCMV, 0 to 3; MCMVdie1, 2 to 22; MCMVrev, 0 to 3). To
ensure that the nondisruption of PML bodies by MCMVdie1
could not be attributed to a general lack of immediate-early
proteins, NIH 3T3 cells were infected with MCMVdie3, an
ie3-deficient mutant (3). In these cells, PML was dispersed in
a similar manner as in parental MCMV-infected cells (Fig. 5A,
compare panels i and j with panels c and d). This result indi-
cates that PML bodies are efficiently disrupted early after in-
fection by an IE1-dependent mechanism and that IE3 is not
involved in this early dispersal. When cultures were analyzed at
15 hpi, surprisingly, a few PML foci were observed in some
parental MCMV-infected cells (Fig. 5A, panels q and r; Fig.
5B), while in cells infected with MCMVdie1, a number of PML
bodies appeared to be disrupted (Fig. 5A, panels s and t; Fig.
5B). At 24 hpi, we observed that, in the MCMVdie1-infected
cells, most PML bodies were also dispersed (Fig. 5A, panels u
to x; Fig. 5B). In cells infected either with mutant or parental
MCMV, PML antigen could be detected in the viral replication
compartments and in foci in the cytoplasm, while in the nuclei
of neighboring uninfected cells, we observed scattered foci.
These data clearly demonstrate that other viral proteins can
disperse PML bodies later during infection independently of
IE1. The more complicated pattern observed at these later
times suggests that PML bodies are slowly disrupted by an
IE1-independent mechanism and that PML is accumulating in
viral replication compartments of MCMV-infected cells, while
PML foci are reformed.
Replication of MCMVdie1 in BALB/c mice. In the next set of
experiments, we sought to evaluate the relevance of IE1 activ-
ity during MCMV infection in vivo. First, we tested our viral
stocks for the absence of BAC vector sequences that could
interfere with the natural course of the infection in mice.
Excision of these sequences has been reported to occur after a
few virus passages in permissive cells via homologous recom-
bination through short identical viral sequences that flank the
BAC vector segment (66). To confirm that the appropriate ex-
cision of the BAC vector sequences had occurred after the
cloning and amplification steps to which the viral stocks were
subjected, PCRs were performed using two different primer
sets and genomic DNA from cells infected with the recombi-
nant viral stocks as templates (66) (see Materials and Methods
for further details). First, reaction assays were performed with
a primer that anneals with the BAC vector sequences and a
second primer that binds to the MCMV EcoRI g fragment.
This primer set should yield a 1,950-bp PCR fragment if the
BAC vector segment was present within the viral genomes or,
alternatively, fail to amplify a product in the absence of these
BAC vector sequences. As expected, a specific PCR-amplified
product was not obtained with this primer set when the DNA
from the recombinant viral stocks was used as a template
(Fig. 6A, lines 2 to 4). In contrast, a 1,950-bp fragment could
be detected in a DNA preparation isolated from a full-length
MCMV BAC plasmid (Fig. 6A, line 1). Thus, the data indi-
cated that BAC-containing genomes were not present in the
recombinant viral stocks. Next, reaction asays were carried out
with a pair of primers that bind to viral sequences flanking the
BAC excision site. This second primer set should either fail to
detect a product in the recombinant viral genomes if the BAC
sequences were present (due to the length of the BAC frag-
ment of approximately 8 kbp) or yield a 590-bp product in the
case that the BAC vector sequences had been correctly excised.
As shown in Fig. 6A, when DNA isolated from any of the three
viral recombinant stocks was used as a template in the reaction
assays, the expected 590-bp fragment was obtained (lanes 6 to
8), while no specific amplified product was detected when using
DNA from the MCMV BAC plasmid (lane 5). In addition, to
further confirm the absence of BAC-containing genomes in
our viral stocks, DNA isolated from the three viral recombi-
nants or the full-length MCMV BAC plasmid was digested
with the restriction enzyme MluI, and a Southern blot analysis
was carried out with a probe (nt 216031 to nt 218468 within the
MCMV sequence) (53) (Fig. 6B) which detects a 12.1-kbp
band in BAC vector-containing viral genomes and a 3.7-kbp
band in BAC-free viral genomes. As shown in Fig. 6C, the
3.7-kbp band, but not the 12.1-kbp band, was present in the
DNA corresponding to the viral stocks (lines 6 to 8), while in
the DNA corresponding to the full-length MCMV BAC, only
the 12.1-kbp band was detected (line 5). Altogether, these
results corroborated that our fibroblast-passaged recombinant
MCMV stocks were homogeneous and that their genomes
were free of BAC vector sequences.
Then we proceeded to analyze the growth properties of
MCMVdie1 in immunocompetent mice. Groups of BALB/c










FIG. 5. MCMVdie1 fails to disrupt PML bodies in NIH 3T3 cells at immediate-early times after infection. NIH 3T3 cells were mock infected
or infected with MCMV, MCMVdie1, MCMVrev, or MCMVdie3 at an MOI of 0.3. At the different times postinfection indicated, cells were fixed
with paraformaldehyde and double labeling was performed for MCMV IE1 or E1 and PML as described in Materials and Methods. DNA was
counterstained with DAPI. (A) Shown are photomicrographs from the different cultures. Panels a to p, 4 hpi; panels q to t, 15 hpi; panels u to x,
24 hpi. IE1 is shown in red (a, c, e, g, i), E1 in red (k, m, o, q, s, u, w), PML in green and black/white, and DAPI in blue. Bars, 10 m. (B) The
number of PML bodies in mock-infected cells and cells infected with MCMV, MCMVdie1, or MCMVrev were counted at the various times after
infection indicated. For mock-infected samples, 100 cells were considered in the quantitation. For infected samples, only infected cells (E1 positive)
were included in the quantitation: at 4 hpi, 100 cells per sample; at 15 hpi, 
50 cells per sample; at 24 hpi, 14 to 29 cells per sample.










mice were injected intraperitoneally with 1  106 PFU of
MCMVdie1 or the parental or revertant MCMVs. At 3, 7, and
14 days postinfection, 6 mice from the MCMVdie1 group and
4 mice from either the parental or revertant MCMV group
were sacrificed, and selected organs were removed to de-
termine levels of viral growth. As seen in Fig. 7, titers of
MCMVdie1 in the spleens, livers, and kidneys of mice infected
for 3 days were reduced at least 7-, 18-, and 3-fold, respectively,
when compared to those in the corresponding organs from
animals infected with the parental MCMV. In a few cases, in
the group of animals infected with MCMVdie1, infectious vi-
rus could not be detected in some of the organs. To calculate
the median values of the viral titers in these groups, the titers
in these particular organs were assigned to be the limit of de-
tection of the assay (5  101 PFU/g). Therefore, the reduction
in those MCMVdie1-infected organs probably represents an
underestimation. On day 7 postinfection, titers of MCMVdie1
in the spleens and livers were approximately 10- and at least
2-fold lower, respectively, than those of the parental MCMV,
while titers in the lungs were similar between mice from the
two groups (Fig. 7). Finally, viral titers in the salivary glands of
the MCMVdie1-infected mice at 14 days were reduced around
fourfold compared to those of the parental MCMV-infected
mice. In a separate experiment, similar results were obtained,
except that titers in the lungs at day 7 after infection were
FIG. 6. Excision of BAC vector sequences from the MCMVdie1 genome. (A) PCRs were carried out using genomic DNAs isolated from a
full-length MCMV BAC (lanes 1 and 5) or from cells infected with the viral stocks of MCMV (lanes 2 and 6), MCMVdie1 (lanes 3 and 7), and
MCMVrev (lanes 4 and 8) as templates. Two distinct primer sets were used to analyze the appropriate excision of the BAC vector sequences (see
Materials and Methods for details). The first primer set includes a primer that binds to the BAC sequence and a primer that anneals with a
sequence located within the EcoRI g fragment (lanes 1 to 4), and the second primer set contains two primers that anneal with MCMV sequences
flanking the excision site (lanes 5 to 8). Amplified products were separated on a 1% agarose gel and visualized by ethidium bromide staining.
Products obtained in the PCR are marked by arrows indicating their sizes. The positions of the size markers are shown on the right. (B) Schematic
representation of the viral genomes before and after excision of the BAC sequences. The probe detects a fragment of 12.1 kbp (before excision
of the BAC sequences) and 3.7 kbp (after excision of the BAC sequences) in MluI-digested viral DNA. Nucleotide positions refer to the MCMV
sequence (53). (C) Ethidium bromide-stained 0.7% agarose gel of MluI-digested viral DNAs from recombinant viral stocks (left panel) and
corresponding Southern blot analysis (right panel). The sizes of the molecular size markers and detected DNA fragments are indicated in the left
and right margins, respectively. Lanes 1 and 5, full-length MCMV BAC; lanes 2 and 6, MCMV; lanes 3 and 7, MCMVdie1; lanes 4 and 8,
MCMVrev. The blot was overexposed to clearly show the absence of signals corresponding to BAC sequences in the viral stock DNAs.
FIG. 7. Growth of MCMVdie1 in different organs of BALB/c mice.
Groups of BALB/c mice (four to six per group) were inoculated in-
traperitoneally with 1  106 PFU of tissue culture-propagated parental
MCMV (gray circles), MCMVdie1 (white circles), or MCMVrev (black
circles). On days 3, 7, and 14 after infection, mice were sacrificed and
the indicated organs removed, weighed, and sonicated as a 10% (wt/
vol) tissue homogenate in DMEM. Viral titers of the resulting homog-
enates were determined by standard plaque assays on NIH 3T3 cells.
Shown are the titers corresponding to the different organs for each
individual mouse within a group. The dashed line shows the detection
limit. Horizontal bars, median values; Saliv., salivary.










significantly lower in MCMVdie1-infected animals than in pa-
rental MCMV-infected mice (data not shown). As expected,
restoration of IE1 expression in the revertant virus resulted in
wild-type replication levels in the different infected organs
analyzed. Taking all of the data together, the MCMV gene ie1
is not essential but influences viral replication in the immuno-
competent host.
Replication of MCMVdie1 in SCID mice. It is known that
MCMV infection is predominantly controlled by CD8 T cells
and that the IE1 protein represents one of the dominant cy-
totoxic T lymphocyte (CTL) targets. While CTLs specific for
peptides derived from MCMV products different than IE1
have been reported to play a prominent role in the control of
MCMV replication, the lack of presentation of IE1 could have
influenced the overall growth capacity of the MCMVdie1 in
the BALB/c animals, thus reducing potential differences that
may exist between the replication of the MCMV lacking ie1
and control viruses in this animal model. Therefore, we exam-
ined the growth properties of MCMVdie1 in CB17 SCID mice,
which are devoid of functional T and B lymphocytes and
Ly49-NK cells. For this purpose, six mice per group were
intraperitoneally inoculated with 1  106 PFU of parental
MCMV, MCMVdie1, or MCMVrev, and on day 7 postinfec-
tion, the spleens, livers, and lungs were extracted and exam-
ined for the presence of infectious virus. As shown in Fig. 8A,
titers of MCMVdie1 in these organs were reduced between 8-
and 27-fold relative to that exhibited by the parental MCMV.
In contrast, mice infected with the revertant virus displayed
viral titers in the target organs examined equivalent to that of
the parental MCMV-infected animals, implying that restora-
tion of the ie1 gene rescues virus replication to wild-type levels.
We then assessed the replication of the viral mutant lacking
the ie1 gene at a later time during the animal infection. CB17
SCID mice were infected as indicated above with the parental,
ie1-defective mutant, or revertant MCMV, and on day 14 after
infection, their spleens, livers, lungs, and salivary glands were
harvested and assayed for infectious virus. Again, viral titers in
the target organs analyzed of the MCMVdie1-infected mice
were reduced by 10- to 60-fold compared to that of the paren-
tal MCMV- or MCMVrev-infected animals (Fig. 8A). The
data demonstrate that MCMVdie1 is markedly attenuated in
replication in most of the target organs of the SCID mice in
comparison to the parental MCMV.
Virulence of MCMVdie1 in SCID mice. To further examine
the importance of the IE1 protein during the MCMV infection
of the immunodeficient animals, we also analyzed the relative
virulence of MCMVdie1, parental, and revertant MCMVs by
comparing their lethality kinetics for SCID mice. Wild-type
MCMV routinely causes death of the SCID mouse when in-
oculated with a dose as low as 3 PFU (50). We intraperitone-
ally inoculated groups of 6 SCID mice with 5  104 PFU of
either MCMVdie1 or the parental or the revertant MCMV,
and survival was monitored daily after infection. The survival
curves are depicted in Fig. 8B, showing a decreased lethality of
MCMVdie1 compared to that of parental MCMV. While mice
infected with parental MCMV succumbed to the infection
within less than 28 days after viral inoculation, mortality in the
MCMVdie1-infected animal group was not detected until 52
days postinfection. As expected, reintroduction of exon 4 of
the ie1 gene in the revertant virus led to a complete reconsti-
tution of the wild-type MCMV phenotype (Fig. 8B). The re-
sults are in good correlation with the in vivo viral growth and
show that, in the absence of IE1, MCMV has lost some of its
virulence. Thus, IE1 activity is required for efficient MCMV
replication and virulence in the immunodeficient mouse.
DISCUSSION
In the present study, we describe the construction of an
MCMV lacking the entire exon 4 of the ie1 gene. We found
that the mutant virus is indistinguishable from the parental
MCMV in its cell culture phenotype in vitro, indicating that
IE1 is totally dispensable for MCMV replication in different
cell types. In marked contrast, we observed that there is an
FIG. 8. Growth and virulence of MCMVdie1 in SCID mice. (A)
Groups of six SCID mice (CB17) were inoculated intraperitoneally
with 1  106 PFU of tissue culture-propagated parental MCMV (gray
circles), MCMVdie1 (white circles), or MCMVrev (black circles). On
days 7 and 14 after infection, mice were sacrificed and the indicated
organs removed, weighed, and sonicated as a 10% (wt/vol) tissue ho-
mogenate in DMEM. Viral titers of the resulting homogenates were
determined by standard plaque assays on NIH 3T3 cells. Shown are the
titers corresponding to the different organs for each individual mouse
within a group. All values were among the limits of detection of the
assay. Horizontal bars, median values. Data shown correspond to re-
sults from one of two independently performed experiments in which
similar results were obtained. (B) Groups of six SCID mice (CB17)
were infected intraperitoneally with 5  104 PFU of either parental
MCMV (gray circles), MCMVdie1 (white circles), or MCMVrev (black
circles) and observed daily for mortality.










important contribution of IE1 to in vivo MCMV pathogenicity
and virulence.
Phenotype of MCMVdie1 in tissue culture. We undertook
the construction of MCMVdie1, a new MCMV defective in ie1,
because we were interested in analyzing the impact of ie1 on
pathogenesis in the natural host in addition to its effect on viral
replication in cultured cells. In a previous study, using the BAC
technology, an MCMV with a truncation in the ie1 gene was
constructed, but the presence of BAC sequences replacing
genomic sequences in this recombinant virus limited its study
in the mouse model (46). For the creation of MCMVdie1, the
entire exon 4 of the ie1 gene was deleted in the backbone of
pSM3fr, an MCMV BAC genome which, after reconstitution
and subsequent passages in permissive cells, results in viral
progeny free of BAC sequences and a wild-type phenotype in
vivo (66). To our surprise, we found that growth of MCMVdie1
was not decreased or delayed compared to that of parental or
revertant MCMV on a variety of cell types known to be sig-
nificant for MCMV infection in vivo. In light of the phenotype
exhibited in fibroblasts by the CMV ie1 mutants described
earlier, we had anticipated that genetic resection of exon 4 of
the ie1 gene, which accounts for most of the amino acid resi-
dues of the IE1 protein, would reduce to some extent the
multicyclic replication of MCMV. The reason for the discrep-
ancy between MCMVdie1 and the previously reported MCMV
bearing the ie1 gene disrupted is not clear at present. The
possibility exists that the stop codon introduced after codon
273 of the IE1 open reading frame in the previously reported
mutant virus results in an aberrant or defective protein with
adverse effects for MCMV growth. Alternatively, this differ-
ence could be attributed, although unlikely, to the distinct
genetic background in which these two mutants were con-
structed. It must also be noted that, in the absence of a rever-
tant virus for the ie1 mutant previously reported, one cannot
completely rule out that the defective phenotype observed
might be due to alterations in other regions of the MCMV
genome outside the IE locus.
To date, the phenotypes observed for the IE CMV mutants
reported so far have been consistent with a model for IE
protein action in HCMV that was postulated in the early 1990s
(21, 62) mainly based on transient-transfection assays. This
model considered the capacity of IE2 to negatively autoreg-
ulate its own promoter (the MIE promoter, or MIEP) and
activate HCMV early promoters, together with the ability of
IE1 to stimulate the MIEP and cooperate with IE2 in the
activating effects on early promoters. In this regard, ie2-deleted
HCMV genomes fail to express early genes and are thereby
incapable of making progeny virus (41). Similarly, resection of
IE3 also results in an incompetent MCMV unable to progress
in the viral life cycle beyond the IE phase (3). An important
prediction of this model is that the levels of IE1 provide a key
determinant (positive loop) in the switch from IE to E gene
expression. The basic tenets of this model seem to certainly
hold true for HCMV infection at a low MOI. HCMV ie1
mutants display a growth defect under conditions of low viral
input that was attributed to the inability of IE1 to efficiently
activate HCMV delayed-early gene transcription (20). This
IE1 requirement for HCMV growth is circumvented at a high
MOI, despite a slight delay in the accumulation of delayed-
early genes. The finding reported here that MCMVdie1 grows
with the same efficiency as wild-type MCMV in vitro suggests
that there must be subtle differences in the functioning of IE1
from HCMV and MCMV in tissue culture cells or that alter-
native compensating mechanisms to IE1 activities operate dur-
ing MCMV infection. In this connection, it is possible that IE
proteins, virion transactivators, cellular components or other
events triggered upon viral attachment or penetration may be
sufficient in MCMV to substitute for IE1. We have not ana-
lyzed in detail viral gene expression in MCMVdie1-infected
cells under low-MOI conditions to ascertain whether a positive
feedback and/or the transactivation of early genes are defec-
tive. However, when infected with high doses of the ie1-deleted
virus, at least levels of IE3 and E1 protein do not seem to be
significantly altered in NIH 3T3 cells (Fig. 2). Regardless, if
differences exist in the extent of immediate-early and early
transcription between MCMVdie1 and parental MCMV infec-
tions, they do not appear to have an effect on the overall
efficiency of MCMV growth. Altogether, the fact that the ie1
gene can be deleted without compromising MCMV replication
in vitro indicates a higher independency of MCMV on func-
tions of its more predominant IE protein than of HCMV.
The availability of an MCMV unable to express IE1 permit-
ted further investigation of IE1 activities in the context of the
viral infection. A number of DNA viruses, including adenovi-
ruses and herpesviruses, are known to perturb the speckled
macromolecular nuclear domains, named PML bodies during
their life cycle (reviewed in references 17 and 42). These PML
bodies consist of many proteins, but their structural cohesion
as a nuclear body is dependent on the presence of sumoylated
PML (43, 49). Viral proteins expressed very early in infection
target to PML bodies and disaggregate them either by degrad-
ing PML or by depleting sumoylated forms of PML. PML
bodies are preferential sites for the beginning of viral tran-
scription and DNA replication (17, 42). A recent observation
with HSV suggests that PML bodies may also be formed de
novo near entering viruses (58). While the precise role that
their disruption plays in viral infection remains to be eluci-
dated, it has been proposed that these processes are of crucial
importance for the establishment of loci of efficient viral tran-
scription and DNA replication, in particular under low-MOI
conditions. IE1 is the HCMV component to which this PML
dispersal activity has been assigned, and in agreement,
HCMV-defective ie1 mutants fail to disrupt PML bodies (1, 2,
30, 35, 70). Tang and Maul (63) recently showed that trans-
fected MCMV IE1 had the capacity to disperse PML bodies in
fibroblasts. The results presented in the present study are in
agreement with these observations and show, using the mutant
virus, that essentially no loss of PMLs could be detected at
early times (4 hpi) after infection with MCMVdie1. Experi-
ments using HCMV or herpes simplex virus (HSV) with dis-
ruptions of the corresponding PML body dispersal products
(IE1 and ICP0, respectively) together with experiments that
employ cell lines that either do not express or overexpress
PML suggest that active IE1/ICP0 is needed to counteract a
repressive action of PML bodies, particularly under low-MOI
conditions (references 2, 9, 18, and 48 and references therein).
Thus, the MOI-dependent phenotype of the IE1-defective
HCMV was interpreted as a threshold effect resulting from the
titration of the cellular repression mechanism by an increasing
viral genome load. In the case of MCMV, our findings that a










mutant MCMV lacking IE1 has replication kinetics similar to
wild-type MCMV independently of the viral input indicates
that, regardless of IE1 levels, MCMV overcomes the lack of
PML disruption early during infection. A quantitative analysis
of the number of PML bodies per nucleus at 15 h and, in
particular, at 24 h after MCMVdie1 infection indicates that
indeed a significant number of these are dispersed. This ob-
servation suggests that when MCMV infection progresses, a
second, IE1-independent, mechanism becomes available that
is capable of disrupting PML bodies. At these late times, im-
munofluorescence staining showed increased levels of PML
distributed over the cytoplasm, in small scattered foci in the
nucleus, and accumulating in the viral replication compart-
ments outlined by E1 staining. These increased PML levels are
in agreement with previous observations (63) shown by West-
ern blotting that PML is not destroyed by MCMV infection as
it is in HSV infections but is instead present in increasing levels
during MCMV infection. Altogether, our findings with cul-
tured cells confirm those of Tang and Maul (63) in that
MCMV IE1 plays a primary role in the dispersion of PML
bodies, extending them to the context of the viral infection and
identifying an IE1-independent mechanism for
MCMV-induced PML disruption. This mechanism does not
degrade PML but prevents the formation of PML bodies,
probably by affecting the sumoylation status of PML (49).
Furthermore, we demonstrate that lack of IE1 and immediate
disruption of PML bodies after infection does not limit the
replication potential of MCMVdie1 in cultured cells.
We cannot discard the possibility that the processes dis-
cussed above might have a role in vivo and may determine in
part the attenuated phenotype linked to MCMVdie1 in the
mouse model. It is known that interferon increases the size and
number of PML bodies in cultured cells. Under low-MOI con-
ditions, HSV infection does not progress after interferon treat-
ment, except in those rare cells in which the PML bodies are
dispersed (55, 64). In fact, interferon has been shown to re-
press HSV infection in part via a PML-dependent pathway (12,
13). It may be that in an in vivo situation, initial MCMV in-
fection induces an interferon response that increases the levels
of PML in surrounding cells. When these cells are then in-
fected, the increased PML levels may take longer to be over-
come by the IE1-independent mechanism, thus delaying the
effect of the infection.
Whether MCMV IE1 is involved in other activities that have
been attributed to HCMV IE1, such as altering the cell cycle or
preventing apoptosis in infected cells, remains a topic for fu-
ture studies. However, along the course of our experiments,
we did not detect major alterations in cells infected with
MCMVdie1 that could be related to these processes. In this
sense, it must be noted that other CMV products have been
described as having antiapoptotic properties and disturbing the
cell cycle under different settings (7, 23, 44, 69, 71). This func-
tional redundancy most likely reflects the various strategies
developed by the virus to adapt to the different conditions
encountered in vivo.
Phenotype of MCMVdie1 during infection in vivo. Despite
the absence of a phenotype for MCMVdie1 in tissue culture
cells, we found that IE1 functions are important for viral rep-
lication in a natural setting. First, we detected markedly re-
duced viral titers during the acute phase of infection of the
ie1-defective virus in most of the organs examined in immu-
nocompetent and immunodeficient mice compared to ani-
mals infected with parental MCMV. Secondly, in the SCID
model of virulence, we observed a substantial delay in mor-
tality of approximately 35 days among animals infected with
MCMVdie1 compared to those inoculated with control vi-
ruses. The fact that a revertant from MCMVdie1 and the
parental wild type grew equally well in both types of mice and
displayed similar virulence degrees in the SCID mice excludes
the possibility that alterations in MCMVdie1 other than dele-
tion of exon 4 of the ie1 gene could account for the debilitated
phenotype of this virus in vivo. Thus, loss of IE1 clearly leads
to reduced MCMV disease, but IE1 is not absolutely required
for MCMV multiplication in vivo. Beyond question, the ie1-
defective mutant was still virulent in that virus could be de-
tected in all of the organs analyzed from the infected mice and
no SCID mice survived longer than 63 days after infection with
MCMVdie1. This is in marked contrast to the completely avir-
ulent phenotype found for the enhancerless MCMV (22),
which most likely reflects the results of low levels of both IE1
and IE3, a gene product shown to be absolutely essential for
early and late MCMV protein synthesis, in functionally signif-
icant amounts.
The reason for the attenuated phenotype of MCMV in the
absence of IE1 is unclear at present. It must be noted that in
MCMV, the IE1 protein provides the major immunodominant
CTL target, with the 168YPHFMPTNL176 nonapeptide being
the dominant CTL epitope. Thus, a plausible outcome of re-
moving the IE1 epitope could have been that MCMVdie1
would replicate more robustly in the BALB/c mice. However,
in this connection, studies with different viral systems have
shown that, in the absence of an immunodominant viral epi-
tope, subdominant epitopes are unveiled, thereby maintaining
an effective and complete immune control. As an example, a
peptide derived from the m164 protein has been reported to
play an immunodominant role during the early and late phases
of the MCMV replication cycle (28). Importantly, the reduced
growth of MCMVdie1 was detected shortly after infection in
primary target organs, such as the liver and spleen. It is pos-
sible that the mutant virus is partially impaired per se to enter
or replicate in certain cell types at primary sites in infected
animals, thereby limiting the levels of progeny virus available
for infection of secondary target cells. Although the growth
kinetics of MCMVdie1 are not altered in a variety of cultured
cells, we cannot exclude a defect in replication in other cell
types not analyzed in vitro (i.e., hepatocytes) or subjected to
specific conditions, such as in different growth, activation, or
differentiation states. A decreased ability of this mutant to
spread from the site of inoculation to the visceral organs or
from those to other secondary organs or tissues might also
contribute to the MCMVdie1 phenotype observed in the
mouse. However, in this sense, the mutant virus exhibited
kinetics similar to and reached titers identical to those of the
corresponding controls in peritoneal macrophages extracted
from BALB/c mice. Alternatively or simultaneously, a specific
virus-host interaction-related phenomenon could be influenc-
ing the reduced viral growth of MCMVdie1. IE1 could be
interfering with some early immune innate response. The de-
fective growth and significant attenuation of MCMVdie1 even
in the absence of B, CTL, and NK (Ly49H) responses in the










SCID mouse model might indicate that IE1 targets the host’s
interferon responses. Thus, MCMV could be interfering with
the interferon-induced antiviral state by means of its more
predominantly expressed IE protein and favoring in this man-
ner its replication.
Whether, HCMV IE1 behaves in a fashion similar to that of
MCMV IE1 during the infection of its host remains an open
question. But based on the poor growth displayed by the de-
fective ie1 mutant at low multiplicities in vitro, one should
predict that, in the absence of IE1, HCMV would be more
severely affected than MCMV, resulting in a highly attenuated
or even completely avirulent phenotype in its host.
Latency and reactivation from latency are key aspects of
CMV pathogenesis. At the molecular level, these events have
been suggested to be determined by the activity of IE gene
products. Importantly, Kurz and Reddehase (37) have re-
ported that reactivation is controlled at several checkpoints,
the first of which is at the level of the MIEP. Moreover, they
show that, in the lungs of latently infected mice, the ie1 gene is
transcribed, while ie3-specific transcripts are not detected (38).
The viability of MCMVdie1 in the mouse model allows an
assessment of the role of IE1 in the latency reactivation cycle.
It should be noted, however, that the generalized defect in
replication of MCMVdie1 in the mouse might influence the
final load of latent viral genomes in target organs (54). While
it has been reported that there is not a straight correlation
between the extent of CMV replication in organs during the
primary infection and the levels to which the virus is able to
establish latency and reactivate (5), the attenuated phenotype
of MCMVdie1 must be taken into consideration when drawing
conclusions about rates of reactivation.
In summary, the work presented here formally demonstrates
that, without being an essential player, IE1 is pivotal in the
replicative strategies of MCMV in the natural host. Further
studies with this ie1-defective MCMV together with the gen-
eration of new recombinant viruses bearing specific mutations
in regions of the IE1 protein and its subsequent evaluation in
the mouse model will contribute in future work to a more
complete understanding of IE1 activities in vivo.
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